T cell therapy for the treatment of cachexia and chronic diseases
The present invention relates to compositions and methods for the use of T cells and more particularly, activated T cells, in the treatment and/or amelioration of diseases associated with a proinflammatory state, such as cachexia, chronic diseases such as chronic renal failure, and hepatitis.
1 . A method for ameliorating a disease associated with a proinflammatory state in an individual, comprising
a. contacting a population of cells, wherein at least a portion of the population comprises T cells, from an individual afflicted with the disease, with a surface wherein said surface has attached thereto a first agent which stimulates a TCR/CD3 complex-associated signal in the T cells and a second agent that binds the CD28 accessory molecule on the surface of the T cells, thereby activating the T cells;
b. administering the activated T cells to the individual;
thereby ameliorating the disease associated with a proinflammatory state in the individual.
2 . The method of claim 1 wherein the disease is a chronic inflammatory condition selected from the group consisting of chronic cardiac disease, chronic lung disease, chronic renal failure, hepatitis, chronic autoimmune disease, and chronic infections.
3 . The method of claim 1 wherein the disease is cachexia.
4 . The method of any one of claims 1 - 3 wherein the ameliorating comprises a reduction in serum levels of one or more proinflammatory cytokines as compared to levels prior to administering the activated T cells.
5 . The method of claim 3 wherein the treatment leads to an increase in body weight.
6 . The method of claim 3 wherein the treatment leads to any one or more of an increase in energy level, an increase in ECOG performance status, and an increase in Karofsky performance status.
7 . The method of claim 1 wherein the first agent is an antibody or an antigen-binding fragment thereof.
8 . The method of claim 7 wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.
9 . The method of claim 7 wherein the antibody is an anti-CD3 antibody.
10 . The method of claim 1 wherein the second agent is an antibody or an antigen-binding fragment thereof.
11 . The method of claim 10 wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.
12 . The method of claim 10 wherein the antibody is an anti-CD28 antibody.
13 . The method of claim 1 wherein the first and the second agents are both antibodies or antigen-binding fragments thereof.
14 . The method of claim 13 wherein the first agent is an anti-CD3 antibody or antigen-binding fragments thereof and the second agent is an anti-CD28 antibody or antigen-binding fragments thereof.
15 . The method of claim 1 wherein the second agent is a natural ligand of CD28.
16 . The method of claim 15 wherein the natural ligand is B7-1.
17 . The method of claim 1 wherein said surface is a solid surface.
18 . The method of claim 1 wherein said surface is a cell surface.
19 . The method of claim 1 wherein said surface is a paramagnetic bead.
20 . The method of claim 1 wherein said first and said second agent are covalently attached to said surface.
21 . The method of claim 1 wherein said first and said second agent are noncovalently attached to said surface.
22 . The method of claim 1 wherein said first and said second agent are indirectly attached to said surface.
23 . A method for treating a disease associated with a proinflammatory state, comprising administering activated T cells to an individual afflicted with the disease;
thereby treating the disease associated with a proinflammatory state.
24 . The method of claim 23 wherein the disease is a chronic inflammatory condition selected from the group consisting of chronic cardiac disease, chronic lung disease, chronic renal failure, hepatitis, chronic autoimmune disease, and chronic infections.
25 . The method of claim 23 wherein the disease is cachexia.
26 . The method of any one of claims 23 - 25 wherein the treatment results in a reduction in serum levels of one or more proinflammatory cytokines as compared to levels prior to administering the activated T cells.
27 . The method of claim 23 wherein the treatment leads to an increase in body weight.
28 . The method of claim 23 wherein the treatment leads to any one or more of an increase in energy level, an increase in ECOG performance status, and an increase in Karofsky performance status.